United Therapeutics Statistics
Share Statistics
United Therapeutics has 45.11M
shares outstanding. The number of shares has increased by 1.23%
in one year.
| Shares Outstanding | 45.11M |
| Shares Change (YoY) | 1.23% |
| Shares Change (QoQ) | 0.6% |
| Owned by Institutions (%) | 98.76% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 20,019 |
| FTD / Avg. Volume | 3.87% |
Short Selling Information
The latest short interest is 1.97M, so 4.36% of the outstanding
shares have been sold short.
| Short Interest | 1.97M |
| Short % of Shares Out | 4.36% |
| Short % of Float | 5.73% |
| Short Ratio (days to cover) | 5.15 |
Valuation Ratios
The PE ratio is 13.34 and the forward
PE ratio is 10.39.
United Therapeutics's PEG ratio is
0.52.
| PE Ratio | 13.34 |
| Forward PE | 10.39 |
| PS Ratio | 5.54 |
| Forward PS | 3.3 |
| PB Ratio | 2.47 |
| P/FCF Ratio | 14.76 |
| PEG Ratio | 0.52 |
Financial Ratio HistoryEnterprise Valuation
United Therapeutics has an Enterprise Value (EV) of 14.55B.
| EV / Sales | 5.06 |
| EV / EBITDA | 8.8 |
| EV / EBIT | 10.96 |
| EV / FCF | 13.47 |
Financial Position
The company has a current ratio of 5.25,
with a Debt / Equity ratio of 0.05.
| Current Ratio | 5.25 |
| Quick Ratio | 5.03 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 0.18 |
| Debt / FCF | 0.28 |
| Interest Coverage | 32.1 |
Financial Efficiency
Return on Equity is 18.55% and Return on Invested Capital is 16.14%.
| Return on Equity | 18.55% |
| Return on Assets | 16.23% |
| Return on Invested Capital | 16.14% |
| Revenue Per Employee | $2,204,904.21 |
| Profits Per Employee | $915,785.44 |
| Employee Count | 1,305 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 1.96 |
Taxes
| Income Tax | 343.9M |
| Effective Tax Rate | 22.35% |
Stock Price Statistics
The stock price has increased by 17.6% in the
last 52 weeks. The beta is 0.58, so United Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.58 |
| 52-Week Price Change | 17.6% |
| 50-Day Moving Average | 301.98 |
| 200-Day Moving Average | 343.67 |
| Relative Strength Index (RSI) | 57.97 |
| Average Volume (20 Days) | 517,111 |
Income Statement
In the last 12 months, United Therapeutics had revenue of 2.88B
and earned 1.2B
in profits. Earnings per share was 26.44.
| Revenue | 2.88B |
| Gross Profit | 2.57B |
| Operating Income | 1.38B |
| Net Income | 1.2B |
| EBITDA | 1.65B |
| EBIT | 1.58B |
| Earnings Per Share (EPS) | 26.44 |
Full Income StatementBalance Sheet
The company has 1.7B in cash and 300M in
debt, giving a net cash position of 1.4B.
| Cash & Cash Equivalents | 1.7B |
| Total Debt | 300M |
| Net Cash | 1.4B |
| Retained Earnings | 7.22B |
| Total Assets | 7.74B |
| Working Capital | 3.22B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 1.33B
and capital expenditures -246.5M, giving a free cash flow of 1.08B.
| Operating Cash Flow | 1.33B |
| Capital Expenditures | -246.5M |
| Free Cash Flow | 1.08B |
| FCF Per Share | 23.91 |
Full Cash Flow StatementMargins
Gross margin is 89.24%, with operating and profit margins of 47.86% and 41.53%.
| Gross Margin | 89.24% |
| Operating Margin | 47.86% |
| Pretax Margin | 53.49% |
| Profit Margin | 41.53% |
| EBITDA Margin | 57.5% |
| EBIT Margin | 47.86% |
| FCF Margin | 37.55% |
